| 2024 |
| 09/19 | 1,743 | 1,762 | 1,717 | 1,732 | +1.29% | 5,966,700 | 3兆1343億 | -2.26% |
| 09/18 | 1,696 | 1,720 | 1,690 | 1,710 | +1.24% | 5,122,200 | 3兆945億 | -3.39% |
| 09/17 | 1,718 | 1,721 | 1,644 | 1,689 | -0.94% | 13,870,600 | 3兆565億 | -4.41% |
| 09/13 | 1,785 | 1,805 | 1,699 | 1,705 | -4.75% | 11,212,800 | 3兆854億 | -3.4% |
| 09/12 | 1,789 | 1,815 | 1,786 | 1,790 | +0.62% | 4,828,500 | 3兆2392億 | +1.47% |
| 09/11 | 1,800 | 1,805 | 1,769 | 1,779 | -0.67% | 4,952,100 | 3兆2193億 | +1.08% |
| 09/10 | 1,820 | 1,825 | 1,789 | 1,791 | -1.32% | 6,105,700 | 3兆2411億 | +2.11% |
| 09/10 | （空売り報告）BNP Paribas Financial Markets SNC 7,192,592株（0.39%）-0.11%義務消失 |
| 09/09 | 1,788 | 1,820 | 1,773 | 1,815 | +0.78% | 4,246,500 | 3兆2845億 | +3.83% |
| 09/09 | （空売り報告）BNP Paribas Financial Markets SNC 9,227,792株（0.5%）新規 |
| 09/06 | 1,795 | 1,814 | 1,795 | 1,801 | +0.33% | 4,454,300 | 3兆2592億 | +3.21% |
| 09/05 | 1,762 | 1,802 | 1,756 | 1,795 | -0.22% | 4,682,700 | 3兆2483億 | +3.1% |
| 09/04 | 1,773 | 1,799 | 1,769 | 1,799 | -1.15% | 5,693,000 | 3兆2555億 | +3.39% |
| 09/03 | （IR情報）15:00 無担保普通社債発行に関するお知らせ |
| 09/03 | 1,790 | 1,822 | 1,786 | 1,820 | +1.56% | 3,609,200 | 3兆2935億 | +4.78% |
| 09/02 | 1,820 | 1,820 | 1,783 | 1,792 | -1.38% | 3,628,200 | 3兆2429億 | +3.46% |
| 08/30 | 1,820 | 1,826 | 1,801 | 1,817 | -0.6% | 7,693,800 | 3兆2881億 | +5.15% |
| 08/29 | 1,819 | 1,835 | 1,815 | 1,828 | +0.72% | 5,467,400 | 3兆3080億 | +6.16% |
| 08/28 | 1,810 | 1,821 | 1,796 | 1,815 | -0.06% | 4,352,200 | 3兆2845億 | +5.77% |
| 08/28 | （IR情報）8:30 抗体ー薬物複合体PADCEV(エンホルツマブベドチン)進行性尿路上皮がん患者の一次治療を対象としたペムブロリズマブとの併用療法について欧州で承認を取得 |
| 08/27 | 1,794 | 1,817 | 1,790 | 1,816 | +1.17% | 4,172,900 | 3兆2863億 | +6.26% |
| 08/26 | 1,793 | 1,802 | 1,774 | 1,795 | -1.81% | 4,282,200 | 3兆2483億 | +5.46% |
| 08/23 | 1,816 | 1,828 | 1,807 | 1,828 | +0.66% | 6,488,600 | 3兆3080億 | +7.78% |
| 08/22 | 1,760 | 1,816 | 1,752 | 1,816 | +3.77% | 11,372,000 | 3兆2863億 | +7.39% |
| 08/21 | 1,730 | 1,760 | 1,727 | 1,750 | +2.22% | 8,680,300 | 3兆1669億 | +3.86% |
| 08/20 | 1,712 | 1,725 | 1,703 | 1,712 | +1.66% | 5,587,100 | 3兆981億 | +1.78% |
| 08/20 | （IR情報）8:30 抗体ー薬物複合体PADCEV(エンホルツマブベドチン)中国で承認を取得 |
| 08/19 | 1,716 | 1,716 | 1,678 | 1,684 | -1.86% | 5,475,600 | 3兆474億 | +0.3% |
| 08/16 | 1,723 | 1,724 | 1,700 | 1,716 | +1.18% | 5,322,000 | 3兆1053億 | +2.2% |
| 08/15 | 1,674 | 1,701 | 1,669 | 1,696 | +1.01% | 4,777,000 | 3兆691億 | +1.25% |
| 08/14 | 1,671 | 1,680 | 1,643 | 1,679 | +1.76% | 6,432,600 | 3兆384億 | +0.42% |
| 08/13 | 1,624 | 1,650 | 1,623 | 1,650 | +1.16% | 7,812,200 | 2兆9859億 | -1.2% |
| 08/09 | 1,675 | 1,686 | 1,620 | 1,631 | -2.97% | 11,915,400 | 2兆9515億 | -2.22% |
| 08/08 | 1,663 | 1,701 | 1,651 | 1,681 | -0.77% | 5,602,000 | 3兆420億 | +0.84% |
| 08/07 | 1,600 | 1,714 | 1,600 | 1,694 | +4.12% | 10,922,400 | 3兆655億 | +1.8% |
| 08/06 | 1,676 | 1,722 | 1,584 | 1,627 | -0.61% | 17,489,700 | 2兆9443億 | -1.93% |
| 08/05 | 1,685 | 1,722 | 1,621 | 1,637 | -6.19% | 15,812,000 | 2兆9624億 | -1.27% |
| 08/02 | 1,735 | 1,763 | 1,696 | 1,745 | +1.81% | 18,644,600 | 3兆1578億 | +5.37% |
| 08/01 | （IR情報）15:00 条件付対価に関わる公正価値変動額の計上について |
| 08/01 | （IR情報）15:00 2025年3月期第1四半期決算短信[IFRS](連結) |
| 08/01 | （IR情報）15:00 2025年3月期第1四半期決算説明会資料 |
| 08/01 | （IR情報）15:00 2025年3月期第1四半期決算補足資料 |
| 08/01 | 1,737 | 1,737 | 1,698 | 1,714 | -1.95% | 7,111,300 | 3兆1017億 | +3.88% |
| 07/31 | 1,732 | 1,749 | 1,719 | 1,748 | +1.04% | 9,633,600 | 3兆1632億 | +6.26% |
| 07/30 | 1,720 | 1,730 | 1,711 | 1,730 | +1.11% | 7,916,900 | 3兆1307億 | +5.62% |
| 07/29 | 1,699 | 1,715 | 1,687 | 1,711 | +1.3% | 7,789,200 | 3兆963億 | +4.84% |
| 07/29 | （IR情報）8:30 ゾルベツキシマブ欧州CHMPが販売承認勧告を採択 |
| 07/29 | （IR情報）8:30 PADCEV(エンホルツマブベドチン)進行性尿路上皮がん患者の一次治療を対象としたペムブロリズマブとの併用療法について欧州CHMPが販売承認勧告を採択 |
| 07/26 | 1,678 | 1,698 | 1,666 | 1,689 | +1.5% | 6,282,900 | 3兆565億 | +4% |
| 07/25 | 1,660 | 1,670 | 1,642 | 1,664 | +0.24% | 5,379,100 | 3兆112億 | +2.91% |
| 07/24 | 1,650 | 1,672 | 1,645 | 1,660 | +0.36% | 4,592,100 | 3兆40億 | +3.11% |
| 07/23 | 1,642 | 1,657 | 1,639 | 1,654 | +1.04% | 3,627,400 | 2兆9931億 | +3.12% |
| 07/22 | 1,644 | 1,648 | 1,621 | 1,637 | -0.3% | 3,501,400 | 2兆9624億 | +2.44% |
| 07/19 | 1,657 | 1,663 | 1,625 | 1,642 | -3.24% | 9,695,600 | 2兆9714億 | +3.08% |
| 07/18 | 1,687 | 1,704 | 1,678 | 1,697 | +0.53% | 6,558,100 | 3兆709億 | +6.93% |
| 07/17 | 1,667 | 1,698 | 1,666 | 1,688 | +1.99% | 6,754,100 | 3兆547億 | +6.7% |
| 07/16 | 1,656 | 1,660 | 1,644 | 1,655 | -0.12% | 4,617,800 | 2兆9949億 | +4.88% |
| 07/12 | 1,655 | 1,665 | 1,648 | 1,657 | -0.3% | 6,881,900 | 2兆9986億 | +5.21% |
| 07/11 | 1,645 | 1,665 | 1,643 | 1,662 | +1.96% | 7,450,300 | 3兆76億 | +5.73% |
| 07/10 | 1,625 | 1,632 | 1,612 | 1,630 | 0% | 6,399,000 | 2兆9497億 | +3.89% |
| 07/09 | 1,612 | 1,635 | 1,607 | 1,630 | +1.24% | 5,509,000 | 2兆9497億 | +3.95% |
| 07/08 | 1,625 | 1,632 | 1,604 | 1,610 | -0.43% | 8,737,900 | 2兆9135億 | +2.81% |
| 07/05 | 1,615 | 1,623 | 1,605 | 1,617 | +0.81% | 6,136,600 | 2兆9262億 | +3.45% |
| 07/04 | 1,592 | 1,605 | 1,584 | 1,604 | +0.88% | 4,112,200 | 2兆9026億 | +2.75% |
| 07/03 | （5%ルール）アペリオ・グループ・エルエルシー(Aperio Group,…（0.1%）ブラックロック(ネザーランド)BV(BlackRock (Neth…（0.29%）ブラックロック(ルクセンブルグ)エス・エー(Black…（0.09%）ブラックロック・アセット・マネジメント・アイルラ…（0.82%）ブラックロック・アセット・マネジメント・カナダ・…（0.12%）ブラックロック・アドバイザーズ・エルエルシー(B…（0.08%）ブラックロック・インスティテューショナル・トラス…（1.36%）ブラックロック・インベストメント・マネジメント(…（0.12%）ブラックロック・インベストメント・マネジメント(…（0.2%）ブラックロック・インベストメント・マネジメント・…（0.09%）ブラックロック・ジャパン（2.1%）ブラックロック・ファンド・アドバイザーズ(Black…（2.07%）ブラックロック・ファンド・マネジャーズ・リミテッ…（0.31%）ブラックロック・フィナンシャル・マネジメント・イ…（0.06%） |
| 07/03 | 1,585 | 1,595 | 1,583 | 1,590 | +0.13% | 4,632,300 | 2兆8773億 | +2.12% |
| 07/02 | 1,584 | 1,592 | 1,569 | 1,588 | -0.06% | 6,589,400 | 2兆8737億 | +2.12% |
| 07/02 | （IR情報）8:30 前立腺がん治療剤XTANDI中国で適応追加に関する承認を取得 |
| 07/01 | 1,591 | 1,593 | 1,567 | 1,589 | -0.06% | 6,761,000 | 2兆8755億 | +2.25% |
| 06/28 | 1,605 | 1,609 | 1,585 | 1,590 | -0.56% | 8,161,300 | 2兆8773億 | +2.38% |
| 06/27 | 1,578 | 1,614 | 1,566 | 1,599 | +0.95% | 13,702,400 | 2兆8936億 | +2.96% |
| 06/26 | 1,576 | 1,599 | 1,567 | 1,584 | +0.32% | 8,991,800 | 2兆8665億 | +2.13% |
| 06/25 | 1,565 | 1,588 | 1,558 | 1,579 | +1.02% | 5,825,900 | 2兆8574億 | +1.94% |
| 06/24 | 1,542 | 1,567 | 1,537 | 1,563 | +2.16% | 6,467,800 | 2兆8285億 | +1.17% |
| 06/21 | 1,495 | 1,538 | 1,494 | 1,530 | +2.2% | 9,711,900 | 2兆7687億 | -0.84% |
| 06/20 | 1,499 | 1,504 | 1,488 | 1,497 | -0.4% | 3,873,000 | 2兆7090億 | -2.92% |
| 06/19 | 1,501 | 1,509 | 1,494 | 1,503 | -0.13% | 4,073,500 | 2兆7199億 | -2.53% |
| 06/18 | 1,507 | 1,512 | 1,488 | 1,505 | -0.33% | 5,067,000 | 2兆7235億 | -2.46% |
| 06/17 | 1,507 | 1,513 | 1,496 | 1,510 | +0.53% | 4,709,900 | 2兆7325億 | -2.2% |
| 06/14 | 1,483 | 1,510 | 1,482 | 1,502 | -0.33% | 11,925,300 | 2兆7181億 | -2.72% |
| 06/13 | 1,556 | 1,556 | 1,503 | 1,507 | -3.83% | 8,194,700 | 2兆7271億 | -2.46% |
| 06/12 | 1,563 | 1,569 | 1,549 | 1,567 | -0.76% | 4,191,000 | 2兆8357億 | +1.36% |
| 06/11 | 1,590 | 1,597 | 1,574 | 1,579 | +0.13% | 5,214,100 | 2兆8574億 | +2.2% |
| 06/10 | 1,596 | 1,597 | 1,568 | 1,577 | -0.82% | 4,848,900 | 2兆8538億 | +2.07% |
| 06/07 | 1,583 | 1,601 | 1,579 | 1,590 | +0.19% | 5,106,700 | 2兆8773億 | +2.98% |
| 06/06 | 1,595 | 1,603 | 1,583 | 1,587 | -0.5% | 6,315,400 | 2兆8719億 | +2.99% |
| 06/05 | 1,566 | 1,600 | 1,566 | 1,595 | +1.14% | 7,577,200 | 2兆8864億 | +3.64% |
| 06/04 | 1,550 | 1,580 | 1,543 | 1,577 | +1.22% | 6,620,700 | 2兆8538億 | +2.74% |
| 06/03 | 1,563 | 1,570 | 1,545 | 1,558 | +0.58% | 5,259,600 | 2兆8194億 | +1.83% |
| 05/31 | （IR情報）11:30 ゾルベツキシマブFDAが承認再申請を受理 |
| 05/31 | 1,537 | 1,554 | 1,531 | 1,549 | +1.91% | 19,855,300 | 2兆8031億 | +1.44% |
| 05/30 | 1,525 | 1,528 | 1,501 | 1,520 | -1.04% | 7,142,200 | 2兆7506億 | -0.26% |
| 05/29 | 1,555 | 1,558 | 1,526 | 1,536 | -1.73% | 6,325,100 | 2兆7796億 | +0.92% |
| 05/28 | 1,564 | 1,570 | 1,552 | 1,563 | -0.45% | 4,676,000 | 2兆8285億 | +2.83% |
| 05/27 | 1,566 | 1,585 | 1,556 | 1,570 | +0.26% | 6,702,600 | 2兆8411億 | +3.56% |
| 05/24 | 1,546 | 1,572 | 1,543 | 1,566 | +0.32% | 6,817,200 | 2兆8339億 | +3.57% |
| 05/23 | 1,530 | 1,571 | 1,526 | 1,561 | +2.56% | 10,295,300 | 2兆8248億 | +3.51% |
| 05/22 | 1,508 | 1,533 | 1,504 | 1,522 | +1.33% | 5,685,700 | 2兆7543億 | +1.26% |
| 05/21 | 1,503 | 1,510 | 1,497 | 1,502 | -0.66% | 3,960,000 | 2兆7181億 | -0.2% |
| 05/20 | 1,493 | 1,529 | 1,492 | 1,512 | +1.68% | 5,813,700 | 2兆7362億 | +0.27% |
| 05/17 | 1,509 | 1,511 | 1,481 | 1,487 | -1.78% | 8,169,500 | 2兆6909億 | -1.59% |
| 05/16 | 1,525 | 1,530 | 1,510 | 1,514 | -0.72% | 4,790,700 | 2兆7398億 | -0.07% |
| 05/15 | （IR情報）16:00 国内外の当社グループ幹部に対する業績連動型株式報酬制度および業績連動型株式交付制度の継続に関するお知らせ |
| 05/15 | （IR情報）16:00 業績連動型株式報酬制度の継続に関するお知らせ |
| 05/15 | 1,525 | 1,538 | 1,521 | 1,525 | +0.26% | 4,901,000 | 2兆7597億 | +0.39% |
| 05/14 | 1,518 | 1,536 | 1,514 | 1,521 | +0.66% | 6,123,400 | 2兆7524億 | -0.07% |
| 05/13 | 1,519 | 1,523 | 1,501 | 1,511 | -1.11% | 4,597,000 | 2兆7344億 | -0.92% |
| 05/10 | 1,537 | 1,550 | 1,519 | 1,528 | -0.84% | 6,638,000 | 2兆7651億 | -0.07% |
| 05/09 | 1,540 | 1,545 | 1,518 | 1,541 | -0.26% | 5,938,700 | 2兆7886億 | +0.46% |
| 05/08 | 1,556 | 1,568 | 1,545 | 1,545 | -1.15% | 7,330,800 | 2兆7959億 | +0.46% |
| 05/07 | 1,561 | 1,574 | 1,543 | 1,563 | +0.32% | 7,722,200 | 2兆8285億 | +1.36% |
| 05/02 | 1,525 | 1,567 | 1,517 | 1,558 | +2.16% | 8,944,300 | 2兆8194億 | +0.84% |
| 05/01 | 1,514 | 1,536 | 1,510 | 1,525 | +0.73% | 6,920,400 | 2兆7597億 | -1.61% |
| 04/30 | 1,514 | 1,523 | 1,498 | 1,514 | +0.53% | 10,248,700 | 2兆7398億 | -2.7% |
| 04/26 | 1,482 | 1,506 | 1,446 | 1,506 | +3.51% | 13,564,300 | 2兆7253億 | -3.59% |
| 04/25 | （IR情報）15:00 2024年3月期決算説明会資料 |
| 04/25 | （IR情報）15:00 2024年3月期決算補足資料 |
| 04/25 | （IR情報）15:00 2024年3月期決算短信[IFRS](連結) |
| 04/25 | （IR情報）15:00 コアベースの業績の定義変更について |
| 04/25 | （IR情報）15:00 役員の異動について |
| 04/25 | 1,471 | 1,485 | 1,453 | 1,455 | -0.95% | 8,318,300 | 2兆6330億 | -7.21% |
| 04/24 | （IR情報）8:30 前立腺がん治療剤XTANDI欧州で適応追加に関する承認を取得 |
| 04/22 | （IR情報）8:30 過活動膀胱治療剤「Myrbetriq」仮差し止め請求に関する米国デラウェア州連邦地方裁判所の決定について |
